PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.

pdx news

  • PDX pharma awarded SBIR grant from the National Cancer Institute (total of $2.4M) for the development of PETTRA, a novel lung cancer treatment

    7/6/2023
    read more

  • CEO of PDX Pharma selected as a semi-finalists at the AIM-HI Women’s Venture Competition in Oncology

    5/3/2023
    read more

  • PDX Pharma awarded two-year $1.87M phase II SBIR grant from the National Cancer Institute (NCI) for the development of ARAC-02, a novel lung cancer treatment

    2/21/2023
    read more

Copyright © 2017 PDX Pharmaceuticals, Inc. All rights reserved